as of 02-06-2026 2:54pm EST
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 65.4M | IPO Year: | N/A |
| Target Price: | $16.00 | AVG Volume (30 days): | 41.2K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.70 - $18.00 | Next Earning Date: | 03-18-2026 |
| Revenue: | $800,000 | Revenue Growth: | -89.95% |
| Revenue Growth (this year): | -92.3% | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -44101000.0 | FCF Growth: | N/A |
See how IMA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "IMA ImageneBio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.